Amphiphysin Ab, CSF, ANNA-1, CSF, ANNA-2, CSF, ANNA-3, CSF, Anti-Hu, Antineuronal Cerebellar Antibodies, CRMP-5-IgG, CSF, Dorsal Root Ganglion Antibody, Hu Antibody, Neuron Restricted Autoantibodies, Neuronal Nuclear Antibody, Neuronal-Anti, Ovarian Cancer-Related Antibodies, Paraneoplastic Autoantibody Western Blot Confirmation, CSF, Paraneoplastic Neurological Autoimmunity, PCA-1, CSF, PCA-2, CSF, PCA-Tr, CSF, Purkinje Cell Cytoplasmic Antibodies, Ri, Anti, Yo-Anti
Aids in the diagnosis of paraneoplastic neurological autoimmune disorders related to carcinoma of lung, breast, ovary, thymoma, or Hodgkin lymphoma in spinal fluid specimens
In patients with a history of tobacco use or other lung cancer risk, or if thymoma is suspected, PAVAL / Paraneoplastic Autoantibody Evaluation, Serum is also recommended.
Provide the following information:
-Relevant clinical information
-Ordering provider name, phone number, mailing address, and e-mail address
AGN1C, AMPHC, AMPIC, ANN1C, ANN2C, ANN3C, CRMC, DPPIC, DPPTC, GABIC, GL1IC, GL1TC, NMDIC, PCA1C, PCA2C, PCTRC: Indirect Immunofluorescence Assay (IFA)
CRMWC: Western Blot
AGNBC, AMIBC, AN1BC, AN2BC, PC1BC, PCTBC: Immunoblot (IB)
GD65C, VGKCC: Radioimmunoassay (RIA)
AMPCC, CS2CC, DPPCC, GABCC, GL1CC, LG1CC, NMDCC: Cell-Binding Assay (CBA)
Antibodies directed at onconeural proteins shared by neurons, glia, muscle, and certain cancers are valuable serological markers of a patient's immune response to cancer. They are not found in healthy subjects, and are usually accompanied by subacute neurological symptoms and signs. Several autoantibodies have a syndromic association, but no autoantibody predicts a specific neurological syndrome. Conversely, a positive autoantibody profile has 80% to 90% predictive value for a specific cancer. It is not uncommon for more than one paraneoplastic autoantibody to be detected, each predictive of the same cancer.